The report classifies the Global Hereditary Angioedema Treatment Market in various segments and offer a comprehensive overview. The Global Hereditary Angioedema Treatment Market to gain from increasing incidences of genetic mutation.
Pune, India – May 16, 2019 —
The Global Hereditary Angioedema Treatment Market is anticipated to expand at a CAGR of 16.8% and reach US$ 6533.3 Mn by the end of 2025. The report classifies the global hereditary angioedema treatment market in various segments and offer a comprehensive overview. The Global Hereditary Angioedema Treatment Market to gain from increasing incidences of genetic mutation. Recently Fortune Business Insights, published a report titled, “Hereditary Angioedema Treatment Market Size, Share and Global Trend by Drug Class (C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors), Application (Prophylaxis, Treatment), Route of Administration (IV, Subcutaneous), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) and Geography Forecast till 2025.” As per the report, the global hereditary angioedema treatment market was worth US$ 1883.1 Mn in 2017.
According to the report, the hereditary angioedema treatment market in North America was valued at US$ 1752.2 Mn in 2017. The growth witnessed is attributable to the high prevalence of hereditary angioedema in the region. North America may remain dominant in the global market through the forecast period (2018-2025) also. Presence of an established healthcare system and increasing healthcare expenditure are a few factors anticipated to contribute to the expansion of the hereditary angioedema treatment market in North America.
The report also predicts the market in Asia Pacific to witness impressive growth. Increasing medical tourism in nations such as China and India will create lucrative growth opportunities for the market in the region. Besides this, an increasing number of product innovations in the region backed by the high presence of hereditary angioedema drugs manufacturers will give tailwinds to the growth witnessed by the hereditary angioedema treatment market.
C-1 Esterase Inhibitor Segment to Dominate Global Market During Forecast Period
In terms of drug class, the C-1 esterase inhibitor is the most popular drug and dominated the global hereditary angioedema treatment market in 2017. The segment accounted for 61.3% of the global market in 2017. The trend is unlikely to change during the forecast period 2018-2025 owing to the drug’s reliability among patients and practitioners.
Increasing awareness about the disorder and rising prevalence of the hereditary angioedema are some factors expected to drive the global hereditary angioedema treatment market during the forecast period. Additionally, technological developments in the hereditary angioedema treatment devices and equipment are expected to boost the global market.
According to the U.S. Hereditary Angioedema Association, hereditary angioedema may not necessarily occur due to the prior familial history of the disease. In 25% of the cases, hereditary angioedema may arise due to spontaneous mutation of the gene called C-1 inhibitor. This is anticipated to enable growth in the global hereditary angioedema treatment market.
Browse Complete Report Details at https://www.fortunebusinessinsights.com/industry-reports/hereditary-angioedema-treatment-market-100164
On the flip side, the side effects and high cost associated with hereditary angioedema drugs and treatment is the major factor that may restrain the global hereditary angioedema treatment market.
Shire, CSL Behring, and Pharming Group NV to Lead the Global Market
The Global Hereditary Angioedema Treatment Market is witnessing the entry of new players in the market. However, at present Pharming Group NV, Shire, and CSL Behring are together leading the global market owing to the organization’s strong distribution network. Some of the other companies operating in the global hereditary angioedema treatment market are BIOCRYST PHARMACEUTICALS INC., Ionis Pharmaceuticals Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals Inc., and Adverum.
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Name: Fortune Business Insights
Email: Send Email
Organization: Fortune Business Insights
Address: Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune – 411045, Maharashtra, India
Phone: +1 424 253 0390
This content is not produced by Reuters Editorial News. It is produced by VC NewsNetwork. For content enquiry, please reach us at
Givaudan, the Swiss flavors and fragrances company will be acquiring Golden Frog to strengthen its presence in the Asia Pacific region.
Indonesian ecommerce unicorn Bukalapak has launched BukaGlobal, a new feature that lets consumers outside Indonesia shop on the Bukalapak platform.
This marks Centara’s entry into one of the world’s fastest-growing tourism markets and enables the company to secure a major Myanmar foothold.
This marks the biggest funding round for a fintech company in the SEA region.
The Ubisoft accelerator is bringing its startup incubator programme to Singapore for the first time.